comparemela.com

Latest Breaking News On - Mark irion - Page 4 : comparemela.com

Smilin' Bob's Issues Allergy Alert on Undeclared Egg in

DELPHOS, Ohio, Oct. 20, 2021 (GLOBE NEWSWIRE) Smilin' Bob's is initiating a voluntary recall because a limited amount of Smilin' Bob's Original Smoked.

Delphos
Ohio
United-states
Mark-irion
Drug-administration
Smilin-bob
Original-smoked-fish-dip
Natural-smoked-fish-dip
Smilin-39-bob-s
Egg-allergen
Dish
Food-recall

Herc Holdings Inc. (HRI) Q4 2020 Earnings Call Transcript

Operator Good day and welcome to the Herc Holdings Inc Fourth Quarter 2020 Earnings Conference Call. [Operator instructions] I would now like to turn the conference over to Elizabeth. Please go ahead. Elizabeth Higashi Vice President of Investor Relations Thank you, Grant. And thank you all for joining us this morning. Welcome, everyone, to our fourth quarter and full year 2020 earnings conference call. Earlier today, our press release, presentation slides and 10-K were filed with the SEC and are all posted on our IR website at ir.hercrentals.com. This morning, I m joined by Larry Silber, President and Chief Executive Officer; Aaron Birnbaum, Senior Vice President and Chief Operating Officer; and Mark Irion, Senior Vice President and Chief Financial Officer. We ll review the fourth quarter and full year, our view of the industry and our strategic outlook.

Houston
Texas
United-states
Canada
America
Canadian
Larry-silber
Aaron-birnbaum
Mark-irion
Pro-solutions
Herc-holdings-inc
Herc-holdings-inc-fourth-quarter

Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19

Share this article Share this article METUCHEN, N.J., Jan. 25, 2021 /PRNewswire/ Tevogen Bio today announced it has secured necessary funding from HMP Partners of New Jersey, an investment firm managed by medical doctors, which will allow Tevogen to support all clinical trials of its investigational, potentially curative COVID-19 treatment. Tevogen s Investigational New Drug (IND) application for its proprietary antigen-specific T cell therapy is under review by the U.S. Food and Drug Administration (FDA). All COVID-19 therapeutics utilized to date have sought to slow the progression of the infection and/or moderate its symptoms. These approaches buy time for the patient s own T cells to activate and respond to the infection, which is the mechanism that the body employs to rid itself of viruses such as the SARS-CoV-2. 

New-jersey
United-states
Meadowlands
Pennsylvania
Philadelphia
Saint-michael
Secaucus
Newark
Metuchen
Thomas-jefferson-university
Neal-flomenberg
Tevogen-bio

vimarsana © 2020. All Rights Reserved.